New Research in Genomics Reveals Insights into Rare Genetic Disorders Underdiagnosis

New Research in Genomics

The American College of Medical Genetics and Genomics (ACMG) recently showcased groundbreaking research from Genomics, a techbio company focused on revolutionizing precision healthcare. This research sheds light on the often overlooked issue of underdiagnosis in rare genetic disorders, emphasizing the urgent need for increased awareness and better diagnostic tools.

Focus on Rare Genetic Disorders

The newly presented findings specifically tackle three ultra-rare lysosomal storage disorders that share a common genetic architecture and typically present in childhood. Many patients remain undiagnosed, preventing them from accessing critical, life-saving treatments. These rare conditions, including mucopolysaccharidosis (MPS) types IVA and VI, along with neuronal ceroid lipofuscinosis type 2 (CLN2), have become the focal point of Genomics' research initiative.

Genomics collaborated with BioMarin Pharmaceutical Inc. to deepen the understanding of these genetically defined conditions. The broad scope of research utilized data drawn from global biobanks that included whole-genome and whole-exome sequencing. Such extensive data allowed researchers to detail the prevalence and geographic distributions of the mutations causing these disorders.